Table 1.
Patient characteristics and injected activity.
| Participant | Age [Years] | Sex | Primary | First Diagnosis | Status at Time of Study | Disease State | Mutational Status | Treatment at Time of Study | Injected Activity [MBq] |
|---|---|---|---|---|---|---|---|---|---|
| 01 | 76 | f | Duodenum | 2003 | Omental and liver metastasis | PD | Exon 11 of cKit gene, TRP 557 ARG | Sunitinib | 179 |
| 02 | 72 | f | Ileum | 2012 | Liver metastases | PD | Exon 9 cKit gene | Sunitinib | 127 |
| 03 | 72 | m | Duodenum | 2016 | Liver and lung metastases | SD | Exon 9 cKit gene | Sunitinib | 214 |
| 04 | 83 | f | Stomach | 2014 | Liver metastases | SD | Exon 11 del557-558 Silent mutation PDGFRa P567P, CCA > CCG |
Imatinib | 158 |
| 05 | 50 | f | Stomach | 2016 | Local relapse, liver and peritoneal metastases | PD | Exon 18 D842V of PDGFRa gene | None | 169 |
| 06 | 55 | m | Ileum | 2014 | Liver metastasis | PD | Exon 11 of cKit gene, secondary exon 17 mutation | Sunitinib | 199 |
| 07 | 56 | f | Peritoneal | 2015 | Peritoneal and liver metastases | PD | Exon 11 of cKit gene, PDGF-R wild type | Imatinib | 177 |
| 08 | 56 | f | Stomach | 2001 | Liver, lung | SD | cKit-positive, specific mutation not assessed | Nilotinib | 161 |
| 09 | 56 | m | Small gut | 2004 | Liver, peritoneal metastases | SD | Exon 9 of cKit gene, PDGF-R wild type | Imatinib | 250 |
SD—stable disease, PD—progressive disease. Further data on safety, tolerability and pharmacokinetics in participants 1–6 were previously reported in [25].